top of page
Open Book on Table

TTP PUBLICATIONS

  1. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA, and the Members of the CASG. Comparison of Plasma Exchange with Plasma Infusion in the Treatment of Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine 1991; 325: 393-397. (128)

  2. Rock G, Shumak K, Kelton J, Blanchette V, Buskard N, Spasoff R, and the Members of the CASG. Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchange. Transfusion 1992; 32: 710-714. (131)

  3. Tandon NN, Rock G, Jamieson GA. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura. British Journal of Haematology 1994; 88: 816-825. (138)

  4. Shumak KH, Rock GA, Nair RC and the Canadian Apheresis Group. Late Relapses in Patients Successfully Treated for Thrombotic Thrombocytopenic Purpura. Annals of Internal Medicine 1995;122: 569-572. (140)

  5. Rock G, Shumak K, Sutton D, Buskard N, Nair R and Members of the CAG. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. British Journal of Haematology 1996; 94: 383-386. (142)

  6. Rock G, Kelton JG, Shumak KH, Buskard NA, Sutton DMC and members of the CAG. Laboratory abnormalities in thrombotic thrombocytopenic purpura. British Journal of Haematology 1998; 103: 1031-1036. (152)

  7. Rock, G. and members of the CAG. Influence of Replacement Fluid on TTP: The Experience of the Canadian Apheresis Group. Transfusion Science 1998; 19(3): 199-200. (154)

  8. Wright J, Wang H, Hornstein A, Hogarth M, Mody M, Garvey M, Blanchette V, Rock G, Freedman J. Characterization of platelet glycoproteins and platelet/endothelial cell antibodies in patients with thrombotic thrombocytopenic purpura. British Journal of Haematology 1999; 107: 546-555. (160)

  9. Tsai H-M, Anping L, Rock G. Inhibitors of von Willebrand Factor-Cleaving Protease in Thrombotic Thrombocytopenic Purpura. Clinical Laboratory 2001; 47: 387-392. (175)

  10. Rock, G., Anderson, D., Clark, W., Leblond, P., Palmer, D., Sternbach, M., Sutton, D., Wells, G., Members of the CAG and members of the Canadian Association of Apheresis Nurses. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. British Journal of Haematology 2005; 129: 79-86. (188)

  11. Foley S, Webert K, Arnold D, Rock G, Clark W, Barth D, Sutton D and members of the Canadian Apheresis Group. A Canadian phase II study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura. Kidney International, February 2009, 75 (112) S55-S58 (207)

  12. Cataland SR., Peyvandi F., Mannucci PM., Lammle B., Kremer Hovinga JA., Machin SJ., Scully M., Rock G., Gilbert JC.Yang S. Wu H., Jilma B., Knoebl P. Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. American Journal of Hematology, Volume 87, Issue 4, April 2012, pages 430–432 (213)

  13. Rock GA., Clark WF., Anderson D., Barrett B., Sutton D., Leblond P., Sternbach M., Sontrop J. and Members of the CAG. ADAMTS-13 May Not Predict Disease or Outcome in Patients with Thrombotic Thrombocytopenic Purpura. Thromb Res. 2013, 131(4). (215)

  14. Clark, WF., Rock, G., Foley, R., Barth, David; Webert, K., Yenson, P., Kelton, J., Li, L. A Phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory TTP treated with Rituximab. Br J Haematol., 2015 Jul;170(2):208-17. (219)

  15. Patriquin, C. J., Clark, W. F., Pavenski K., Arnold D.M., Rock G., Foley S. R., for the Canadian Apheresis Group. How we treat thrombotic thrombocytopenic purpura: Results of a Canadian TTP practice survey; Journal of Clinical Apheresis. [Epub: 31 July 2016]. (221)

Logo of Transfusion and Apheresis Science
Logo of World Apheresis Association
bottom of page